Academic Accomplishments 2017
(Inova authors bolded)

ORIGINAL RESEARCH MANUSCRIPTS


REVIEWS


BOOK CHAPTERS AND BOOKS


2. King CS, Nathan SD. Treatment of Pulmonary Hypertension in Interstitial Lung Disease. For Pulmonary Hypertension and Interstitial lung disease. Edited by Robert P. Baughman, Roberto G. Carbone and Steven D. Nathan. Published by Springer 2017

3. Shlobin OA, Nathan SD. Rare ILD and PH. For Pulmonary Hypertension and Interstitial lung disease. Edited by Robert P. Baughman, Roberto G. Carbone and Steven D. Nathan. Published by Springer 2017


PRESENTATIONS AT NATIONAL/INTERNATIONAL MEETINGS


3. Pulmonary Hypertension in Lung Disease: To tweet or not to tweet? Annual Yale Pulmonary Hypertension conference. June 2nd, 2017 (SN)


5. Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia.
6. Incidence of multiple progression events in patients with IPF in the pooled CAPACITY and ASCEND Phase III trials. Podium presentation European Respiratory Society September 12th, 2017 Milan, Italy (SN)

7. Pulmonary Hypertension complicating Interstitial Lung Disease. World Association for Sarcoidosis and Other Granulomatous Disease annual meeting. Beijing, China October 21st, 2018. (SN)


ORIGINAL RESEARCH ABSTRACTS & PRESENTATIONS TO INTERNATIONAL MEETINGS

ISHLT 2017

1. Nayyar M, Shobin OA, King C, Fregoso MF, Verster A, Cochrane A, Nathan SD, Brown AW. Outcomes of Recipients on Dual compared to Triple Immunosuppression after Lung Transplantation. ISHLT 2017


ATS 2017

1. Tsang AK, Shlobin OA, Weir N, King C, Brown AW, Nathan SD. Do Lung function tests predict response to therapy in Connective Tissue Disease (CTD)-Associated Pulmonary Hypertension (PH)?


of Anti-fibrotic Therapy in Idiopathic Pulmonary Fibrosis.


8. Jose A, King C, Nathan SD. The Left and Right Ventricular End Diastolic Pressure Ratio As a Novel Marker of Disease Severity in a Cohort of Patients with Pulmonary Arterial Hypertension.


21. S Braman, B Make, J Lamberti, SD Nathan, N MacIntyre, P Porte, G Criner. Acute Respiratory Failure
That Develops During Hospitalization: A Comparison of Medical vs. Surgical Medicare Patients. Submitted to ATS 2017


24. EH Alhamad, MB Scholand, DA Culver, SD. Nathan, E Carmona, V Kouranos, F Cordova, J Barney, M Wijsenbeek, RP Baughman. Determinants Of Six Minute Walk Distance In Sarcoidosis Associated Pulmonary Hypertension. Submitted to ATS 2017

25. Determinants of Health Related Quality of Life in PAH: Data from The Pulmonary Hypertension Association Registry. Roham Zamanian, David Badesch, Todd Bull, Teresa De Marco, Jeremy Feldman, Jeff Fineman, James Ford, Michael Grey, Dan Grinnan, James Klinger, John McConnell, Erika Berman Rosenzweig, Linda Santos, Oksana Shlobin, Jeff Sager on behalf of PHAR


European Respiratory Society Sep 2017


Chest 2017


5. Patrick Kicker D.J. Franco-Palacios, O.A. Shlobin, Q. Zhao, M. Gomberg-Maitland, Sildenafil for this HFpEF?: Diastolic dysfunction and Gerbode defect induced combined pre and post-capillary pulmonary hypertension.